Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.1.407

Experimental Study on Sustained-release 5-Fluorouracil Implantation in Canine Peritoneum and Para-aortic Abdominalis  

Wei, Guo (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Nie, Ming-Ming (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Shen, Xiao-Jun (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Xue, Xu-Chao (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Ma, Li-Ye (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Du, Cheng-Hui (Department of General Surgery, Changhai Hospital Affiliated to The Second Military Medical University)
Wang, Shi-Liang (Controlled-Release Drug Laboratory, Hefei University of Technology)
Bi, Jian-Wei (Controlled-Release Drug Laboratory, Hefei University of Technology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.1, 2014 , pp. 407-411 More about this Journal
Abstract
Objective: To observe local and systemic toxicity after sustained-release 5-fluorouracil (5-Fu) implantation in canine peritoneum and para-aortic abdominalis and the changes of drug concentration in the local implanted tissue with time. Methods: 300 mg sustained-release 5-Fu was implanted into canine peritoneum and para-aorta abdominalis. Samples were taken 3, 5, 7 and 10 days after implantation for assessment of changes and systemic reactions. High performance liquid chromatography was applied to detect the drug concentrations of peritoneal tissue at different distances from the implanted site, lymphatic tissue of para-aortic abdominalis, peripheral blood and portal venous blood. Results: 10 days after implantation, the drug concentrations in the peritoneum, lymphatic tissue and portal vein remained relatively high within 5 cm of the implanted site. There appeared inflammatory reaction in the local implanted tissue, but no visible pathological changes such as cell degeneration and necrosis, and systemic reaction like anorexia, nausea, vomiting and fever. Conclusions: Sustained-release 5-Fu implantation in canine peritoneum and para-aortic abdominalis can maintain a relatively high tumour-inhibiting concentration for a longer time in the local implanted area and portal vein, and has mild local and systemic reactions. Besides, it is safe and effective to prevent or treat recurrence of gastrointestinal tumours and liver metastasis.
Keywords
Sustained-release 5-Fu; interstitial chemotherapy; peritoneum; para-aortic abdominalis; implants;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Hu XF, Yao J, Gao SG, et al (2013). Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev, 14, 5231-5.   과학기술학회마을   DOI   ScienceOn
2 Alexander HR Jr, Bartlett DL, Pingpank JF, et al (2013). Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery, 153, 779-86.   DOI   ScienceOn
3 Chen WP, He X, Ye QF, et al (2006). Implantation of a drug delivery system during surgery for patients with primary hepatocarcinoma. Hepatobiliary Pancreat Dis Int, 5, 391-5.
4 Davis JL, Pandalai P, Ripley RT, et al (2011). Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials, 12, 129.   DOI
5 Oshima T, Shan J, Okugawa T, et al (2013). Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS One, 8, e74757.   DOI
6 Muchmore JH, Preslan JE, George WJ (1996). Regional chemotherapy for inoperable pancreatic carcinoma. Cancer, 78, 664-73.   DOI
7 Nordlinger B, Rougier P, Arnaud JP, et al (2005). Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol, 6, 459-68.   DOI   ScienceOn
8 Orii T, Karasawa Y, Kitahara H, et al (2013). Long-term survival after sequential chemotherapy and surgery for advanced gastric cancer. Int J Surg Case Rep, 4, 976-80.   DOI   ScienceOn
9 Pohlen U, Rieger H, Kunick-Pohlen S, et al (2007). Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res, 27, 667-74.
10 Wan NB, Zhang L, Zuo CH, et al (2012). Clinical application of intrapertoneal hyperthermo-chemotherapy combined with sustained-release fluorouracil implantation in progressive gastric cancer during surgery. J Chin Phys, 14, 763-6.
11 Zhang X, Zhu H, Wu X, et al (2013). A genetic polymorphism in TOX3 is associated with survival of gastric cancer in a Chinese population. PLoS One, 8, e72186.   DOI
12 Wang R, Wang ZC, Liu XY, et al (2012). An experimental study on local and systemic reactions after sustained-release fluorouracil implantation. Shandong Med J, 14, 763-6.
13 Wang X, Song ZF, Xie RM, et al (2013). Analysis of death causes of in-patients with malignant tumors in Sichuan Cancer Hospital of China from 2002 to 2012. Asian Pac J Cancer Prev, 14, 4399-402.   과학기술학회마을   DOI   ScienceOn
14 Halhsscy MT, Dunn JA, Ward LC, et al (1994). The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in rescetable gastric cancer: five year follow-up. Lancet, 343, 1309-12.   DOI   ScienceOn
15 Zare A, Mahmoodi M, Mohammad K, et al (2013). Survival analysis of patients with gastric cancer undergoing surgery at the Iran cancer institute: a method based on multi-state models. Asian Pac J Cancer Prev, 14, 6369-73.   DOI   ScienceOn
16 Zhang M, Li Z, Zhao B, et al (2011). Predictors of longterm survival in large gastric carcinoma patients. Hepatogastroenterology, 58, 2162-5.
17 Zhang M, Zhang H, Ma Y, et al. Prognosis and surgical treatment of gastric cancer invading adjacent organs. ANZ J Surg, 80, 510-4.
18 Zhou J, Zhou ZP, Cheng S, et al (2008). Clinical research on hypotonic intrapertoneal hyperthermo-chemotherapy combined with fibrin glue sustained-release fluorouracil implantation in progressive gastric cancer during surgery. Chin Arch Gen Surg, 4, 35-7.
19 Jarnagin WR, Schwartz LH, Gultekin DH, et al (2009). Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trialand assessment of DCE-MRI as a biomarker of survival. Ann Oncol, 20, 1589-95.   DOI   ScienceOn
20 Huang B, Sun Z, Wang Z, et al (2013). Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer, 4, 13-57.
21 Kirchhoff T, Zender L, Merkesdal S, et al (2005). Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol, 11, 1091-5.   DOI
22 Link KH, Gansauge F, Gorich J, et al (1997). Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol, 23, 409-14.   DOI   ScienceOn
23 Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.   과학기술학회마을   DOI   ScienceOn
24 Yamamoto M, Baba H, Kakeji Y, et al (2004). Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology, 67, 19-26.   DOI   ScienceOn
25 Yao Z, Guo H, Yuan Y, et al (2013). Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as firstline therapy for advanced gastric cancer. J Chemother, 9, 341-9.
26 Yoney A, Isikli L (2013). Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? Asian Pac J Cancer Prev, 14, 5127-31.   DOI   ScienceOn
27 Yoshimura F, Inaba K, Kawamura Y, et al (2011). Clinical outcome and clinicopathological characteristics of recurrence after laparoscopic gastrectomy for advanced gastric cancer. Digestion, 83, 184-90.   DOI   ScienceOn